A Novel Diagnostic Test to Screen SARS-CoV-2 Variants Containing E484K and N501Y

2 Mutations

- 3 Yanan Zhao^{1,2#}, Annie Lee¹, Kaelea Composto¹, Marcus H. Cunningham¹, Jose R. Mediavilla¹,
- 4 Samantha Fennessey³, André Corvelo³, Kar Fai Chow⁴, Michael Zody³, Liang Chen^{1,2}, Barry N.
- 5 Kreiswirth^{1,2,5}, David S. Perlin^{1,2,5#}

1

6

13

14

15

- ¹Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA
- ²Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA
- 9 ³New York Genomic Center, NY 10013, USA
- ⁴Core Laboratory, Department of Pathology, Hackensack University Medical Center,
- 11 Hackensack, NJ 07110, USA
- ⁵Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA

- # Address correspondence to Yanan Zhao, Ph.D. yanan.zhao@hmh-cdi.org, phone: 201-880-
- 17 3503, or David S. Perlin, Ph.D. david.perlin@hmh-cdi.org, phone: 201-880-3500

ABSTRACT

Spike protein mutations E484K and N501Y carried by SARS-CoV-2 variants have been associated with concerning changes of the virus, including resistance to neutralizing antibodies and increased transmissibility. While the concerning variants are fast spreading in various geographical areas, identification and monitoring of these variants is lagging far behind, due in large part to the slow speed and insufficient capacity of viral sequencing. In response to the unmet need for a fast and efficient screening tool, we developed a single-tube duplex molecular assay for rapid and simultaneous identification of E484K and N501Y mutations from nasopharyngeal swab (NS) samples within 2.5 h from sample preparation to report. Using this tool, we screened a total of 435 clinical NS samples collected from COVID patients at 8 hospitals within the Hackensack Meridian Health network in New Jersey. While B.1.351 and P.1 variants were absent from the current study, our data revealed a dramatic increase in the frequency of E484K over time, underscoring the need for continuous epidemiological monitoring.

Key words: SARS-CoV-2, variants, E484K, N501Y, screening

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has plagued human society causing immeasurable losses in an unprecedented way. In the circumstances, many monoclonal and polyclonal antibodies have been approved for clinical use and several vaccines have been licensed with two mRNA vaccines and one viral vectored vaccine being rolled out for population vaccination in various countries and geographical areas. Opposed to these encouraging progresses and facts, this virus has quickly adapted to various pressures from antiviral therapy and host immunity and evolved independently into several SARS-CoV-2 variants of concern (VOC). These variants, including B.1.1.7 (a.k.a. 501Y.V1). B.1.351(a.k.a. 501Y.V2), and P.1(a.k.a. 501Y.V3) variants, are concerning because they either resist neutralizing antibody and possibly reduce vaccine efficacy or show increased transmissibility, via making some key mutations in the spike protein [1, 2, 3, 4, 5]. Studies have shown that currently observed resistance to neutralizing antibody is largely associated with the E484K mutation [1, 2, 5, 6, 7]. Previously, E484K was only harbored by B.1.351 and P1 variants. The most recent report found that the E484K has been successfully incorporated into some isolates of the B.1.1.7 variant [8]. Moreover, the new variant of interest discovered in New York (B.1.526) also carries the E484K mutation, and alarmingly, fast-spreading over the past two months [9, 10]. Another key spike mutation, N501Y, present in all three VOCs is considered to enhance the binding between spike and the ACE2 receptor in human cells, thus contributing to increased transmissibility and possibly virulence as well [11, 12, 13]. As we continue to understand the impact of these variants on the mode of the ongoing pandemic, efficient and continuous monitoring of these variants is critical to implementation of fast and effective countermeasures to eventually defeat this devastating disease. The closer this genotyping can happen to the testing, the quicker the data can be used and actioned. To this end, we developed a novel molecular diagnostic assay capable of identifying the signature mutations within 2.5 h from sample preparation to report, and used this tool to screen clinical

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

nasopharyngeal swabs (NS) collected from COVID patients at Hackensack Meridian Health (HMH) network hospitals from late December 2020 to February 2021. This novel genotyping is based on the thermal dynamic difference of molecular beacon (MB) binding with perfectly complementary target or mismatch target. To generate single-stranded target DNA for the MB probe, an asymmetric reverse transcription (RT)-PCR assay was developed to amplify the mutation hotspot region covering both 484 and 501 codons of the S gene (supplemental material). Upon completion of thermal cycling, a melting curve analysis is performed to characterize dissociation between the single-stranded DNA product and two differentially labeled MB probes, to enable simultaneous genotyping at both loci. Owing to the probe design, the wildtype (WT) template is expected to generate a higher melting temperature (Tm) than that of the mutated genotype at corresponding locus. As shown on Fig. 1, E484 WT is featured for a Tm at 54.85°C \pm 0.19°C, \sim 5°C higher than the Tm of E484K (49.81°C \pm 0.07°C). Similarly, the signature Tm for N501 WT was 59.97°C ± 0.09°C, higher than 54.78°C ± 0.12°C for N501Y. In a blinded fashion, this test correctly genotyped RNA samples extracted from 6 different reference viral strains, including one WT (SARS-CoV-2 USA WA1/2020), two B.1.1.7 variants (SARS-CoV-2 hCoV-19/USA/CA_CDC_5574/2020 and SARS-CoV-2 hCoV-19/England/204820464/2020), and two B.1.351 variants (SARS-CoV-2 hCoV-19/South Africa/KRISP-EC-K005321/2020 and SARS-CoV-2 hCoV-19/South Africa/KRISP-K005325/2020) purchased from BEI resources, and one E484K variant isolate recently obtained from our network hospital. The analytical sensitivity of the assay was evaluated against 10-fold serial dilutions of RNA prepared from each of the reference viral strain. The assay can reliably identify as low as 200 copies of 484WT, 200 copies of E484K, 20 copies of 501WT, and 200 copies of N501Y per reaction, respectively.

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

Using this tool, we next accessed to SARS-CoV-2 positive NS specimens through the HMH institutional Biorepository under an HMH-IRB approved protocol Pro2018-1022, to screen the signature mutations. This study also accessed de-identified data for time and location of sample collection through the HMH-IRB approved protocol, Pro2020-0342. A total of 435 samples received in February 2021 from 8 HMH hospitals with a cycle of threshold (Ct) value <37 in SARS-CoV-2 N2 RT-PCR test [14] were subjected to the spike mutation screening. To speed up the screening procedure, we adopted an extraction-free sample process method by heat inactivating a 50 µl aliquot of swab specimen in the presence of proteinase K at 95°C for 5 min [15], prior to genotyping test. As a result, 365 and 376 samples yielded identifiable signals for 484 and 501 sites, respectively. The proportion of E484K was 8.8% (32/365), and it was 8.0% (30/376) for N501Y. Of note, the presence of E484K and N501Y in the tested samples was completely independent. Co-harboring of both mutations was not observed in our screening. In addition, we discovered a new genotype at the 501-probe binding site from 11 samples (11/376, 2.9%), which thereafter was confirmed to be a N501T (AAT>ACT) mutation in subsequent sequencing. The melting profile of N501T is markedly different from that of WT and N501Y, with a signature Tm of 56.41°C ± 0.15°C. A sharp increase was noticed in both E484K and N501Y prevalence in February compared to earlier months. E484K cases account for 12.0% (29/242) of all samples in February. In contrast, it was not detected in samples of December (n=28), and only 3.2% (3/95) of samples of January were E484K positive. The N501Y followed the same trend, with 11.2% (28/251) prevalence in February, and 1.0% (1/98) and 3.7% (1/27) in January and December, respectively. Further analysis by sample collection source found that E484K scattered in various hospitals, whereas N501Y seemed to be highly concentrated in one hospital area (20/107 vs. 10/249, P=0.001), indicating a possible small outbreak which warrants further investigation.

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

We next performed whole genome sequencing (WGS) with a panel of 74 samples representing different genotypes flagged by this screening tool, including 24 E484K, 25 N501Y, 5 N501T, and 20 WT at 484 and 501 loci. Indeed, WGS results are 100% consistent with our genotyping determination. Genomic analysis (Fig. S) showed that the majority of the E484K cases (n=19) fell within the B.1.526 lineage, a recent clone emerged from New York, and the rest belong to clade 20C B.1 lineage (n=2), and clade 20B under R.1 (n=2) and B.1.1.309 lineage (n=1), respectively. All N501Y cases except one are members of B.1.1.7 lineage. Currently, WGS is being used as the main tool for epidemiological monitoring of SARS-CoV-2 variants. However, the relatively long turn-around-time for WGS and the demand on bioinformatic expertise for data analysis makes identification of concerning variants lagged far behind laboratory COVID diagnosis. Clearly, there is an unmet need for faster and simpler screening tool that can be used in a high-throughput fashion to increase the capacity of SARS-CoV-2 variant detection in real-time. Herein, we demonstrate that a novel and easy molecular diagnostic assay can be used as a convenient tool for large scale of SARS-CoV-2 variant screening, thus, to enable highly efficient epidemiological monitoring. Not only the assay is proved to be highly accurate in our clinical screening, notably, it is also sensitive to new mutations within the probe binding site. This has been well exemplified by our discovery of the N501T mutation from the clinical specimens. To our knowledge, this is the first report of using novel screening tool to identify key mutation harboring SARS-CoV-2 variants in NJ hospitals. B.1.351 and P.1 variants were absent from the current study, however our data revealed a dramatic increase in the frequency of E484K over time, underscoring the need for continuous epidemiological monitoring. A couple of limitations of this study need to be noted. Firstly, this novel screening assay is slightly less sensitive than the widely used RT-PCR COVID diagnostic assay. Therefore,

samples with very low viral load (eg: N2 Ct >35) may not yield identifiable signal in this genotyping test. Efforts towards improving the sensitivity of the test is ongoing. Secondly, the current assay only aims at picking up mutations at 484 and 501 loci. It is our intention to keep expanding and updating this test by adding new mutations associated with important phenotypic change, to better respond to the fast-evolving situation.

ACKNOWLEDGMENTS

This work was supported by the COVID Emergency Research Fund #61315, Hackensack University Medical center; by funds provided to the CDI by Activision Publishing Inc, Suez North America, and by *NJ Stands Up to COVID*. The funders of this study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. All authors declare no conflict of interest in this work. Whole genome sequencing was performed at the New York Genome Center (NYGC) as part of the COVID-19 Genomic Research Network (CGRN) with funds generously provided by NYGC donors.

We thank Steven Park, Nathaly Cabrera, and Timothy Mikulski for technical support of viral culture and RNA extraction.

REFERENCES

- Diamond M, Chen R, Xie X, et al. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. Research square. 2021 Feb 10. doi: 10.21203/rs.3.rs-228079/v1. PubMed PMID: 33594356; PubMed Central PMCID: PMCPMC7885928. eng.
- Gröhs Ferrareze PA, Franceschi VB, de Menezes Mayer A, et al. E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil. 2021:2021.01.27.426895. doi: 10.1101/2021.01.27.426895 %J bioRxiv.

162	3.	Kupferschmidt K. Fast-spreading U.K. virus variant raises alarms. Science (New York,
163		NY). 2021 Jan 1;371(6524):9-10. doi: 10.1126/science.371.6524.9. PubMed PMID:
164		33384355; eng.
165	4.	Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization
166		by South African COVID-19 donor plasma. Nature medicine. 2021 2021/03/02. doi:
167		10.1038/s41591-021-01285-x.
168	5.	Wang P, Nair MS, Liu L, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351
169		and B.1.1.7. Nature. 2021 Mar 8. doi: 10.1038/s41586-021-03398-2. PubMed PMID:
170		33684923; eng.
171	6.	Andreano E, Piccini G, Licastro D, et al. SARS-CoV-2 escape in vitro from a highly
172		neutralizing COVID-19 convalescent plasma. bioRxiv: the preprint server for biology.
173		2020 Dec 28. doi: 10.1101/2020.12.28.424451. PubMed PMID: 33398278; PubMed
174		Central PMCID: PMCPMC7781313 Emanuele Andreano, Ida Paciello, Elisa Pantano,
175		Noemi Manganaro and Rino Rappuoli are listed as inventors of full-length human
176		monoclonal antibodies described in Italian patent applications n. 102020000015754 filed
177		on June 30(th) 2020 and 102020000018955 filed on August 3(rd) 2020. eng.
178	7.	Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-
179		CoV-2 spike protein variants. eLife. 2020 Oct 28;9. doi: 10.7554/eLife.61312. PubMed
180		PMID: 33112236; PubMed Central PMCID: PMCPMC7723407. eng.
181	8.	Wise J. Covid-19: The E484K mutation and the risks it poses. BMJ (Clinical research
182		ed). 2021 Feb 5;372:n359. doi: 10.1136/bmj.n359. PubMed PMID: 33547053; eng.
183	9.	Annavajhala MK, Mohri H, Zucker JE, et al. A Novel SARS-CoV-2 Variant of Concern,
184		B.1.526, Identified in New York. 2021:2021.02.23.21252259. doi:
185		10.1101/2021.02.23.21252259 %J medRxiv.

186 10. Lasek-Nesselquist E, Lapierre P, Schneider E, et al. The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State. 187 2021:2021.02.26.21251868. doi: 10.1101/2021.02.26.21251868 %J medRxiv. 188 11. Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 189 190 Lineage - United States, December 29, 2020-January 12, 2021. MMWR Morbidity and mortality weekly report. 2021 Jan 22;70(3):95-99. doi: 10.15585/mmwr.mm7003e2. 191 PubMed PMID: 33476315; PubMed Central PMCID: PMCPMC7821772 Journal Editors 192 form for disclosure of potential conflicts of interest. No potential conflicts of interest were 193 194 disclosed. eng. lacobucci G. Covid-19: New UK variant may be linked to increased death rate, early data 195 12. indicate. BMJ (Clinical research ed). 2021 Jan 26;372:n230. doi: 10.1136/bmj.n230. 196 PubMed PMID: 33500262; eng. 197 198 13. Washington NL, Gangavarapu K, Zeller M, et al. Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. 199 medRxiv: the preprint server for health sciences. 2021 Feb 7. doi: 200 201 10.1101/2021.02.06.21251159. PubMed PMID: 33564780; PubMed Central PMCID: 202 PMCPMC7872373. eng. Zhao Y, Cunningham MH, Mediavilla JR, et al. Diagnosis, clinical characteristics, and 203 14. outcomes of COVID-19 patients from a large healthcare system in northern New Jersey. 204 205 Scientific reports. 2021 Feb 23;11(1):4389. doi: 10.1038/s41598-021-83959-7. PubMed 206 PMID: 33623090; PubMed Central PMCID: PMCPMC7902820. eng. Vogels CBF, Watkins AE, Harden CA, et al. SalivaDirect: A Simplified and Flexible 207 15. Platform to Enhance SARS-CoV-2 Testing Capacity. Med (New York, NY). 2020 Dec 26. 208 209 doi: 10.1016/j.medj.2020.12.010. PubMed PMID: 33521748; PubMed Central PMCID: 210 PMCPMC7836249. eng.

Figure 1. Melting profiles for E484WT and E484K (left panel), and those for N501WT and N501Y (right panel). For each genotype, 10-fold serial RNA dilutions containing 2×10⁵ to 200 genome equivalents/reaction were tested. Dashed lines indicate the *Tm* value of corresponding genotype. NTC is the abbreviation for no template control.

